Xintao Qiu

ArticleOnline nowOpen access Affiliations & Notes 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA 2Department of Medicine, Brigham and Women’s Hospital, Boston, MA 02115, USA 3Department of Medicine, Harvard Medical School, Boston, MA 02115, USA 4Institute for Precision Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA 5Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA 6Department of Immunology,...

Abstract Basal breast cancer is a subtype with a poor prognosis in need of more effective therapeutic approaches. Here we describe a unique role for the KDM4C histone lysine demethylase in KDM4C-amplified basal breast cancers, where KDM4C inhibition reshapes chromatin and transcriptomic landscapes without substantial alterations of its canonical substrates, trimethylated histone H3 lysine 9 (H3K9me3) and lysine 36 (H3K36me3).

Results Both KDM5A and KDM5B were reported to be amplified and overexpressed in breast cancer.7,14 However, paralog-specific differences between luminal and basal breast cancer have not been analyzed. Thus, we assessed the mutational landscape of KDM5 paralogs in luminal A (LumA) and basal breast tumors in the TCGA cohort.